close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

314.52 -5.86 (-1.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Insulet’s Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use
From Insulet Corporation
Via Business Wire
Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021
From Insulet Corporation
Via Business Wire
5 Top Stocks for September
Our analysts give you five picks you can add to your portfolio today. 
Via The Motley Fool
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Looking into Insulet's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Insulet (NASDAQ:PODD) earned $26.30 million, a 61.35% increase from the preceding quarter. Insulet also posted a... 
Via Benzinga
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
The 
Via Benzinga
Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States
From Insulet Corporation
Via Business Wire
Insulet Introduces Omnipod DASH® System at Australasian Diabetes Congress
From Insulet Corporation
Via Business Wire
Insulet Stock Dives On Unexpected Delay For Next-Generation Insulin Pump
Insulet said Thursday it expects a one-quarter delay for its next-generation insulin pump, leading PODD stock to tumble on Friday. 
Via Investor's Business Daily
Insulet Corporation (PODD) Q2 2021 Earnings Call Transcript
PODD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year
From Insulet Corporation
Via Business Wire
3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain
Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic. 
Via The Motley Fool
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet to Announce Second Quarter 2021 Financial Results on August 5, 2021
From Insulet Corporation
Via Business Wire
Insulet’s Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 years
From Insulet Corporation
Via Business Wire
Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
Insulet Corp (PODD) Q1 2021 Earnings Call Transcript
PODD earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Insulet Reports First Quarter 2021 Revenue Increase of 27% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet to Present at BofA Securities 2021 Virtual Healthcare Conference
From Insulet Corporation
Via Business Wire
Insulet 2020 Sustainability Report Conveys Strategy to Deliver Growth with Purpose
From Insulet Corporation
Via Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Insulet Announces Pricing of New Senior Secured Credit Facilities
From Insulet Corporation
Via Business Wire
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today